Država: Kanada
Jezik: angleščina
Source: Health Canada
PREGABALIN
BGP PHARMA ULC
N02BF02
PREGABALIN
75MG
CAPSULE
PREGABALIN 75MG
ORAL
60
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0151121003; AHFS:
APPROVED
2005-06-03
_LYRICA (pregabalin) _ _Page 1 of 73_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LYRICA® Pregabalin capsules Capsules, 25, 50, 75, 150, 225, 300 mg, oral Analgesic Agent BGP Pharma ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Initial Authorization: June 3, 2005 Date of Revision: MAR 4, 2024 Submission Control Number: 279480 ®Viatris Specialty LLC BGP Pharma ULC, a Viatris company, Licensee © BGP Pharma ULC, 2024 _ _ _LYRICA (pregabalin) _ _Page 2 of 73_ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2.1 Discontinuing Treatment 03/2024 7 WARNINGS AND PRECAUTIONS, Dependence, Tolerance and/or Abuse Liability 03/2024 7 WARNINGS AND PRECAUTIONS, 7.1.1. Pregnant Women 11/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 R Preberite celoten dokument